Antipsychotic-induced weight gain (Q36211002)

12 August 2017

1 reference

title

Antipsychotic-induced weight gain (English)

1 reference

12 August 2017

1 reference

A J Goudie

1

1 reference

PubMed ID

16050940

12 August 2017

G D Cooper

series ordinal

2

1 reference

PubMed ID

16050940

12 August 2017

J C G Halford

series ordinal

3

1 reference

12 August 2017

1 September 2005

1 reference

Diabetes, Obesity and Metabolism

12 August 2017

1 reference

12 August 2017

7

1 reference

12 August 2017

5

1 reference

12 August 2017

478-487

1 reference

Measurement of appetite disturbances in psychiatric disorders

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Atypical antipsychotics: are some more atypical than others?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Association of olanzapine-induced weight gain with an increase in body fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

The impact of weight gain on quality of life among persons with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

A review of the effect of atypical antipsychotics on weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Weight gain profiles of new anti-psychotics: public health consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Effects of Nefazodone on Body Weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

The implications of weight changes with antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Clozapine's effects on body weight and resting metabolic rate: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Antipsychotic-induced weight gain: bipolar disorder and leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Brain dopamine and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Probing targets for antipsychotic drug action with PET and SPET receptor imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Role of 5-HT1A receptors in the control of food intake in obese Zucker rats of different ages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Norepinephrine and the control of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Clozapine and dopamine D3 receptor antisense reduce cocaine- and amphetamine-regulated transcript expression in the rat nucleus accumbens shell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Studies on modulation of feeding behavior by atypical antipsychotics in female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Metformin for weight loss in pediatric patients taking psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Behavioural management of antipsychotic-induced weight gain: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Schizophrenia and weight management: a systematic review of interventions to control weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Management of weight gain associated with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

A program for managing weight gain associated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Clozapine-induced weight gain predicts improvement in psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

Pharmacogenomics in schizophrenia: the quest for individualized therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00413.X

10.1111/J.1463-1326.2004.00413.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16050940